Epigenetic signature associated with thyroid cancer progression and metastasis

Semin Cancer Biol. 2022 Aug:83:261-268. doi: 10.1016/j.semcancer.2021.03.026. Epub 2021 Mar 27.

Abstract

Thyroid cancer is not among the top cancers in terms of diagnosis or mortality but it still ranks fifth among the cancers diagnosed in women. Infact, women are more likely to be diagnosed with thyroid cancer than the males. The burden of thyroid cancer has dramatically increased in last two decades in China and, in the United States, it is the most diagnosed cancer in young adults under the age of twenty-nine. All these factors make it worthwhile to fully understand the pathogenesis of thyroid cancer. Towards this end, microRNAs (miRNAs) have constantly emerged as the non-coding RNAs of interest in various thyroid cancer subtypes on which there have been numerous investigations over the last decade and half. This comprehensive review takes a look at the current knowledge on the topic with cataloging of miRNAs known so far, particularly related to their utility as epigenetic signatures of thyroid cancer progression and metastasis. Such information could be of immense use for the eventual development of miRNAs as therapeutic targets or even therapeutic agents for thyroid cancer therapy.

Keywords: Epigenetic signature; Metastasis; Non-coding RNA; Thyroid cancer; microRNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epigenesis, Genetic
  • Epigenomics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / genetics
  • Thyroid Neoplasms* / genetics
  • Thyroid Neoplasms* / pathology

Substances

  • MicroRNAs